Frozen Shoulder Embolization

Adhesive capsulitis — commonly called frozen shoulder — is a condition in which the fibrous joint capsule surrounding the shoulder becomes chronically inflamed, thickened, and scarred, dramatically restricting range of motion and causing significant pain. It classically progresses through three phases: the “freezing” phase (gradual onset of pain, worsening motion loss, lasting 3–9 months), the “frozen” phase (persistent stiffness with diminishing acute pain, lasting 9–16 months), and the “thawing” phase (gradual, often incomplete return of motion, lasting 12–24 months). The entire natural history can span 2–3 years — and up to 40% of patients never fully recover range of motion without treatment. It is significantly more common in people with diabetes, thyroid conditions, and those following shoulder injury or surgery.

The current standard of care — physical therapy, corticosteroid injections, and time — has important limitations. Steroid injections offer short-term pain relief but rarely meaningfully alter the disease course when used alone; repeated injections risk tissue atrophy and cartilage damage. Physical therapy can accelerate recovery but is painful in the early stages and requires months of consistent effort. Hydrodilatation (injecting saline to stretch the capsule) helps some patients but has variable durability. Manipulation under anesthesia and surgical capsular release (arthroscopic or open) are reserved for refractory cases and carry risks of bleeding, nerve injury, and prolonged post-operative rehabilitation. The root cause of adhesive capsulitis — inflammatory hypervascularization of the joint capsule — is not addressed by any of these treatments.

Imaging studies using angiography and MRI have demonstrated that frozen shoulder is characterized by dense, abnormal neovascularization (new blood vessel proliferation) within the inflamed joint capsule — particularly the anterior capsule and axillary recess. These new vessels are not normal tissue; they carry inflammatory mediators, pain-signaling substances, and cells that perpetuate the fibrotic cycle. By selectively embolizing these pathologic vessels with tiny microspheres, the inflammatory drive is interrupted at its source. This is the same mechanism underlying GAE for knee arthritis — what researchers now call “inflammatory embolization.” Clinical data show that this approach can break the frozen shoulder cycle much faster than waiting for natural resolution, with 75% of patients reporting meaningful pain relief and improved motion within 8 weeks of the procedure.

Embolization is best suited for patients in the active “freezing” or early-to-mid “frozen” phase, when inflammatory hyperemia is most pronounced. The procedure is particularly valuable in patients who have failed corticosteroid injections and physical therapy and are facing a prolonged course. Patients in the late “thawing” phase with predominantly fibrotic (rather than inflammatory) restriction may benefit less from embolization alone and may still require physical therapy or capsular release for full motion recovery. An MRI or diagnostic angiography helps confirm the presence of active capsular hypervascularization before the procedure is recommended.

The procedure is performed under mild conscious sedation, making it very comfortable. Access is typically through the radial artery at the wrist. A microcatheter is advanced under fluoroscopic guidance to the anterior humeral circumflex artery and its capsular branches. Digital subtraction angiography (DSA) identifies the abnormal hyperemic blush of the inflamed capsule. Microspheres are then gently injected until flow to the neovascular tissue is reduced. Patients may feel mild warmth or pressure in the shoulder during injection — this typically signals that the right territory is being treated. The procedure takes approximately 45–75 minutes. You go home the same day.

In published case series and early clinical trials, most patients begin noticing reduced pain within 2–4 weeks of the procedure. Range of motion improvement typically follows pain relief by 2–6 weeks. By 8 weeks post-procedure, the majority of responders have experienced meaningful functional recovery. Many patients describe the change as “breaking the cycle” — once the inflammatory burden is reduced, physical therapy becomes far more tolerable and productive. It is strongly recommended to resume a gentle physical therapy program 2–4 weeks after embolization to consolidate motion gains.

The embolic particles used for shoulder embolization are calibrated to target only the small-diameter neovascular channels within the capsule, not the normal arteries supplying cartilage, rotator cuff tendons, or humeral bone. Published case series and MRI follow-up studies have found no evidence of avascular necrosis, cartilage damage, or rotator cuff injury following embolization when performed by an experienced operator. The shoulder’s robust collateral arterial supply provides additional protection against non-target ischemia.

Yes — and combining modalities often produces the best results. Embolization addresses the inflammatory vascular component; physical therapy rehabilitates range of motion and strength; and a short course of oral anti-inflammatories can ease post-procedural discomfort. Many patients who had previously found physical therapy intolerable due to pain report a dramatic improvement in their ability to participate in therapy after embolization. A corticosteroid injection can be given 2–4 weeks before embolization in very acute-phase patients to reduce initial procedural discomfort, though it is not required.

Patients with shoulder pain from other causes — rotator cuff tears, glenohumeral osteoarthritis, labral pathology, or biceps tendon disease — are not candidates. A thorough clinical evaluation including MRI is essential to confirm the diagnosis of adhesive capsulitis and rule out structural pathology requiring surgical repair. Patients with prior shoulder surgery or hardware may have altered vascular anatomy that complicates the procedure; feasibility is assessed on a case-by-case basis. General vascular contraindications (severe peripheral arterial disease, contrast allergy) are reviewed at consultation.

Shoulder embolization for adhesive capsulitis is currently an emerging procedure with limited established coverage pathways compared to UFE or PAE. Coverage is variable and often requires a letter of medical necessity documenting failed conventional treatment and imaging confirmation of the diagnosis. Our team will work with your insurer to pursue prior authorization and provide all clinical documentation. We will be transparent about expected out-of-pocket costs prior to scheduling and can discuss self-pay options where insurance coverage is not available.